Clinical logistics · the stretching question
The maintenance interval question: stretching past weekly — what’s known, what isn’t, and who should even ask
Somewhere in every maintenance year the thought arrives: do I still need this every seven days? The honest evidence map: the labels are built on weekly dosing, full stop — interval-stretching (every 10–14 days) is off-label territory with thin formal study, sitting on two supports of very different strength: pharmacokinetic plausibility (half-lives around five days for tirzepatide and seven for semaglutide mean levels taper gradually rather than cliff, so a stretched interval produces lower-but-present coverage, not on-off cycling) and a large folk literature of maintenance patients reporting stable holds at longer intervals — which is anecdote, with all of survivorship’s usual discounts. The legitimate askers: side-effect-limited patients for whom weekly maximum is rough, and stable long-term maintainers whose prescriber is open to a structured experiment. The framework if your prescriber green-lights one: change only the interval, diary everything, pre-commit the retreat trigger — and note the money truth that reframes half these conversations: on per-shipment pricing the question is partly financial; on flat monthly pricing it’s purely clinical, which is where it belongs.
The evidence map — plausibility, anecdote, and the missing middle
What supports the idea: pharmacology — with multi-day half-lives, day ten still carries meaningful drug on board; the taper is a slope, not a cliff, which is also why missed-dose windows exist at all. What’s missing: the middle — controlled maintenance-phase trials of stretched intervals barely exist, so nobody can quote you a regain risk per extra day; the labels don’t sanction it; and the anecdote pile, however large, self-selects its successes. What argues against, concretely: late-interval appetite return is the commonly reported failure mode (days 11–14 getting loud), adherence chaos is the underrated one — a moving injection day breaks the calendar architecture that weekly dosing makes automatic — and any regain that follows gets analytically tangled with everything else in your year. Net reading, stated plainly: plausible, unproven, prescriber-owned — a phrase worth carrying into the conversation verbatim.
Who legitimately asks — and who shouldn’t yet
Legitimate asker one: the side-effect-limited maintainer — stable weight, but weekly dosing keeps a persistent 1–2 on the diary’s score; a longer interval is one of several prescriber levers (dose reduction being the more conventional sibling, and the comparison between them is exactly the clinical conversation). Legitimate asker two: the deep maintainer — a year-plus of held weight, verdict: maintenance, exploring the minimum effective footprint with eyes open. Not yet: anyone mid-titration or inside the first maintenance year (the hold isn’t proven durable enough to experiment against), anyone whose real motive is drift already underway (that’s the audit’s jurisdiction, and stretching would pour fuel on it), and anyone reaching for intervals as a stealth exit ramp — exits deserve their own file’s planning, not a slow-motion improvised one.
The structured experiment — if, and only if, green-lit
The prescriber-approved version has four rules. One variable: interval moves (7→9–10 first, not 7→14), dose stays — changing both un-interprets everything. Full instrumentation: the diary logs every injection date, the 0–3 score, weight weekly same-conditions, plus one new column — late-interval appetite in two words — because that column is the early-warning system. A pre-committed retreat trigger, in writing: “if weight rises X lb over Y weeks, or late-interval appetite scores loud for two cycles, I return to weekly without renegotiating with myself” — the same threshold discipline the restart file teaches, pointed at intervals. A review date: eight to twelve weeks, prescriber on the calendar, verdict rendered on the columns rather than the vibes. Run that way, the experiment answers cleanly in either direction — and “weekly it is” is a perfectly good answer you bought with data instead of drift.
The money truth — what pricing structure does to this question
Under per-shipment or per-vial pricing, stretching intervals quietly becomes a ~30% coupon, and financial gravity starts co-writing your dosing schedule — a genuinely bad author for clinical decisions. Under flat monthly pricing, stretching saves nothing, which sounds like a bug and functions as the feature: the interval question stays purely clinical, argued on side-effect scores and hold-stability rather than invoices — one more quiet argument the structure tier keeps making. (The audited flat plans — $119/$139, dose-proof, month-to-month; compounded, not FDA-approved — are the reference architecture here: pricing that stays out of your dosing ↗) If cost pressure is the honest engine of your interval curiosity, run the cheaper fixes first — the letter, the review, the boards — and let dosing frequency stay a medical dial, not a budgeting one.
FAQ
Can semaglutide or tirzepatide be taken every 10–14 days for maintenance?
It’s off-label with thin formal evidence — pharmacokinetically plausible, anecdotally common, unproven in trials — and belongs exclusively to a prescriber-approved, diary-instrumented experiment with a written retreat trigger.
What’s the main risk of stretching dosing intervals?
Late-interval appetite return and adherence chaos from a moving injection day — plus analytical tangle: any regain becomes hard to attribute, which is why one-variable, instrumented experiments are the only defensible form.
Does stretching intervals save money?
Only under per-shipment pricing — which is exactly the problem, since finances start steering dosing; flat monthly structures keep the question purely clinical.